A Phase 1 interventional study of EI-001 and Placebo in Healthy, sponsored by Elixiron Immunotherapeutics (Hong Kong) Ltd.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-24.
Sponsored by Elixiron Immunotherapeutics (Hong Kong) Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers.
To assess the safety and tolerability of single ascending intravenous (IV) doses of EI-001 in healthy volunteers
To assess the pharmacokinetics (PK) of single ascending IV doses of EI-001 in healthy volunteers
Elixiron Immunotherapeutics (Hong Kong) Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV infusion
Drug: EI-001
IV infusion
Other: Placebo
EI-001 IV infusion
Placebo IV infusion
safety assessment
to assess blood pressure
Time frame: Day 1
safety assessment
to assess heart rate
Time frame: Day 1
safety assessment
to assess respiratory rate
Time frame: Day 1
PK assessment
To assess Maximum observed concentration (Cmax)
Time frame: Day 1
PK assessment
To assess time to maximum observed drug concentration (Tmax)
Time frame: Day 1
PK assessment
to assess AUC from time zero to the last measurable concentration (AUC0-t)
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Jan 2025, 39 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Elixiron Immunotherapeutics (Hong Kong) Ltd.